Drug
Berzosertib clinical trials
Also written VX-970 and M6620.
- studies test it
- 22
- open now
- 0
- in phase 3
- 0
- first study started
- 2012
How studies write it
Studies that test it under each name
Name
- M 6620
- 11
Combined with it in one product
Studies by the year they started
22 studies that test it; most in 2017 (4)
| Year | Studies |
|---|---|
| 2012 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 15
- Phase 2
- 12
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 5 · Other 17
National Cancer Institute (NCI) (14) · EMD Serono Research & Development Institute, Inc. (3) · M.D. Anderson Cancer Center (1) · Merck KGaA, Darmstadt, Germany (1) · Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (1) · University of Oxford (1) · Massachusetts General Hospital (1)
Often tested with
Tested in the same studies.
Irinotecan (2) · Carboplatin (2) · Cisplatin (2) · Avelumab (2) · Topotecan (2) · Gemcitabine (1) · PM 01183 (1) · Sacituzumab govitecan (1)
Studies
Open first, then newest update. How each study uses berzosertib is read from its arms, and is right about nine times in ten.
Testing it · 22
- Berzosertib and Irinotecan in Treating Patients With Progressive, Metastatic, or Unresectable TP53 Mutant Gastric or Gastroesophageal Junction CancerCompletedPhase 2National Cancer Institute (NCI)NCT03641313Written as Berzosertib
- M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castration-Resistant Prostate CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03517969Written as Berzosertib
- M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02595931Written as Berzosertib
- Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung CancerActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04216316Written as Berzosertib
- Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 2National Cancer Institute (NCI)NCT02595892Written as Berzosertib
- Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02627443Written as Berzosertib
- Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT02567422Written as Berzosertib
- Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the LungsActive, not recruitingPhase 2National Cancer Institute (NCI)NCT03896503Written as Berzosertib
- Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and/or Progesterone Receptor Positive, HER2 Negative Breast CancerActive, not recruitingPhase 1National Cancer Institute (NCI)NCT04052555Written as Berzosertib
- A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP InhibitorsCompletedPhase 1/2National Cancer Institute (NCI)NCT04826341Written as Berzosertib
- Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid TumorsActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04266912Written as Berzosertib
- Lurbinectedin With Berzosertib, an ATR Kinase Inhibitor in Small Cell Cancers and High-Grade Neuroendocrine CancersActive, not recruitingPhase 1/2National Cancer Institute (NCI)NCT04802174Written as Berzosertib
- Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedPhase 1/2National Cancer Institute (NCI)NCT02487095Written as VX-970 (M6620)
- Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial CancerCompletedPhase 2National Cancer Institute (NCI)NCT02567409Written as Berzosertib
- ATRi Transition Rollover StudyCompletedPhase 1Merck KGaA, Darmstadt, GermanyNCT03309150Written as Berzosertib
- Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)CompletedPhase 1Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyNCT05246111Written as [14C]Berzosertib
- Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)CompletedPhase 2EMD Serono Research & Development Institute, Inc.NCT04768296Written as Berzosertib
- M6620 Plus Standard Treatment in Oesophageal and Other CancerCompletedPhase 1University of OxfordNCT03641547Written as M6620
- M6620 (VX-970) in Selected Solid TumorsCompletedPhase 2Massachusetts General HospitalNCT03718091Written as M6620
- Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in People With Refractory Solid TumorsCompletedPhase 1National Cancer Institute (NCI)NCT02723864Written as Veliparib + VX-970 + Cisplatin
See all 22 studies that test berzosertib →
Given in every arm · 1 — berzosertib is usual care beside what is tested
Codes
What other systems call berzosertib · ClinicalTrials.gg INT000231
- MeSH (NLM) C000598331berzosertibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) L423PRV3V3BERZOSERTIBConfirmed FDA, NLM, Wikidata
- Wikidata Q27089129berzosertibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C116355BerzosertibOne source FDA
- DrugBank DB11794One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598331 | berzosertib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | L423PRV3V3 | BERZOSERTIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q27089129 | berzosertib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C116355 | Berzosertib | One source FDA |
| DrugBank | DB11794 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.